Advanced techniques in toxicity testing
Posted: 5 August 2024 | Drug Target Review, Molecular Devices | No comments yet
Tune in to this episode where we explore how innovative assays and human-relevant cell models are transforming toxicity screening in drug development.
In this episode titled ‘Advanced techniques in toxicity testing‘, we explore advanced toxicity testing methods.
This conversation features Professor Ruth Roberts, co-director and co-founder at ApconiX and Dr Oksana Sirenko, Senior Scientist at Molecular Devices.
Key learning points:
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
- What strategies can be employed to enhance the predictivity and reliability of toxicity assessments?
- How does high-throughput screening contribute to accelerating drug discovery and development?
- What role can emerging technologies, such as machine learning and AI, play in advancing toxicity testing methods?
This podcast is sponsored by Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.
About the speakers
Professor Ruth Roberts, co-director and co-founder at ApconiX
A director and co-founder of ApconiX, Professor Ruth Roberts has over 25 years of experience in leading drug safety. Ruth is also Chair and Director of Drug Discovery at the University of Birmingham, UK and previously Global Head of Regulatory Safety at AstraZeneca.
Dr Oksana Sirenko, Senior Scientist at Molecular Devices
Dr Oksana Sirenko is the senior manager of assay development at Molecular Devices, working on the development of complex cell-based models for 3D biology, as well as high-content imaging and assay automation.
After developing high-throughput cell-based assays at several biotechnology companies, such as Bayer, Fibrogen, and Bioseek, she became part of the Molecular Devices team as a research scientist in 2009. She is responsible for developing and optimising stem cell-derived 3D models for anti-cancer drug screening, as well as drug toxicity assessment for neurons, the cardiovascular system, and the liver.
Oksana holds a PhD in Biochemistry/Biophysics, has over 15 years of industry experience, and has authored over 35 scientific papers.
Related topics
Cell-based assays, Drug Development, Drug Discovery, High-Throughput Screening (HTS), Ion Channels, Machine learning, Toxicology
Related organisations
ApconiX
Related people
Dr Oksana Sirenko (Molecular Devices), Dr Ruth Roberts (ApconiX)
